Search Result

Results for "

Cytotoxic T lymphocytes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CTLA-4 (8) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (1) Apoptosis (9) Arenavirus (4) Autophagy (1) Bacterial (3) Biochemical Assay Reagents (5) CaMK (1) Caspase (3) CD3 (2) Deubiquitinase (1) EBV (4) EGFR (3) Epigenetic Reader Domain (1) Ferroptosis (1) Fluorescent Dye (1) G-quadruplex (1) HIV (1) HPV (2) HSV (1) IFNAR (1) Influenza Virus (4) Interleukin Related (5) Keap1-Nrf2 (1) LAG-3 (1) MAPKAPK2 (MK2) (2) MHC (8) mRNA (1) NF-κB (2) NO Synthase (2) NOD-like Receptor (NLR) (1) Nuclear Factor of activated T Cells (NFAT) (1) Osteopontin (2) p38 MAPK (2) PD-1/PD-L1 (7) Potassium Channel (1) Proton Pump (1) Pyroptosis (1) RAR/RXR (1) Reference Standards (1) ROR (2) RSV (1) Scavenger Receptor Class B type I (SR-BI） (1) Tim3 (1) TNF Receptor (1) Transmembrane Glycoprotein (5) Tyrosinase (1) VEGFR (2) WDR5 (1)
By Research Areas:	Cancer (60) Infection (11) Inflammation/Immunology (40)
Oligonucleotides:	mRNA (1) Adjuvant (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: CTLA-4

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1724

Concanamycin A Maximum Cited Publications 27 Publications Verification Antibiotic X 4357B; Folimycin; X 4357B	Proton Pump Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H ⁺-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research ^- .

HY-P9901

Ipilimumab 4 Publications Verification MDX-010; BMS-734016	CTLA-4	Cancer
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .

HY-N3005

Britannin 1 Publications Verification	Apoptosis Autophagy NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology Cancer
Britannin is an NLRP3 inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics .

HY-P9948

Alemtuzumab Campath-IH	Apoptosis	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .

HY-P990116

Anti-Mouse osteopontin/SPP1 Antibody (103D6)	Osteopontin	Inflammation/Immunology
Anti-Mouse osteopontin/SPP1 Antibody (103D6) is a mouse-derived anti-mouse osteopontin/SPP1 IgG2c κ type antibody inhibitor. Anti-Mouse osteopontin/SPP1 Antibody (103D6) increases cytotoxic T lymphocyte lytic activity and suppresses colon tumor growth. Anti-Mouse osteopontin/SPP1 Antibody (103D6) ameliorates liver injury in common bile duct ligation (CBDL)-induced primary sclerosing cholangitis mice models .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

HY-163028

ML-T7	Tim3	Cancer
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .

HY-N0591

Dehydrocostus Lactone 2 Publications Verification (-)-Dehydrocostus lactone; Epiligulyl oxide	Bacterial Apoptosis p38 MAPK NF-κB MAPKAPK2 (MK2) Akt NO Synthase Interleukin Related Caspase	Infection Inflammation/Immunology Cancer
Dehydrocostus Lactone ((-)-Dehydrocostus lactone) is a natural sesquiterpene that can be isolated from Saussurea lappa. Dehydrocostus Lactone has multiple activities such as anti-inflammatory, antibacterial, anti-tumor, and immunomodulatory effects. Dehydrocostus Lactone has an MIC of 2 µg/mL against Mycobacterium tuberculosis. Dehydrocostus Lactone can also inhibit the killing activity of cytotoxic T lymphocytes and induce apoptosis in tumor cells .

HY-P99762

Obrindatamab 1 Publications Verification MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P1569

LCMV gp33-41 3 Publications Verification LCMV GP(33-41) M-peptide; gp33 epitope	Arenavirus	Infection Inflammation/Immunology
LCMV gp33-41, the carboxyl-extended 9-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .

HY-P9918

Tremelimumab Ticilimumab; CP-675206	CTLA-4	Inflammation/Immunology Cancer
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .

HY-P99484

Botensilimab AGEN 1181	CTLA-4	Cancer
Botensilimab (AGEN 1181), a human anti-cytotoxic *T-lymphocyte* antigen 4 (CTLA-4)** monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .

HY-172240

Tosposertib TU2218 free base	Anaplastic lymphoma kinase (ALK) VEGFR	Inflammation/Immunology Cancer
Tosposertib (TU2218 free base) is an ALK5/VEGFR2 dual inhibitor (IC₅₀ = 1.2 nM/4.9 nM). Tosposertib directly restores the activity of damaged cytotoxic T lymphocytes (CTLs) and natural killer cells inhibited by TGFβ and suppresses the activity and viability of regulatory T cells. Tosposertib can be used for the study of melanoma and colon cancer .

HY-P4193

AH1	MHC	Inflammation/Immunology Cancer
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8 ⁺ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I L ^d molecule. AH1 can be used for the research of colorectal carcinoma .

HY-P1907

Human Papillomavirus (HPV) E7 protein (49-57)	HPV	Cancer
Human Papillomavirus (HPV) E7 protein (49-57) is a cytotoxic T lymphocyte (CTL) epitope peptide derived from HPV16 E7 protein (sequence: RAHYNIVTF). Human Papillomavirus (HPV) E7 protein (49-57) induces E7_49-57-specific CTL responses. Human Papillomavirus (HPV) E7 protein (49-57) can be used for the research of cervical cancer .

HY-P3333

KSPWFTTL	MHC	Inflammation/Immunology Cancer
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .

HY-P990795

Anti-Mouse osteopontin/SPP1 Antibody (100D3)	Osteopontin	Inflammation/Immunology Cancer
Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonal antibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control (HY-P99981) .

HY-147008

XP-524	Epigenetic Reader Domain	Cancer
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-175802

HBI-2375 HYBI-084	WDR5 Potassium Channel	Inflammation/Immunology Cancer
HBI-2375 (HYBI-084) is a brain-penetrant WDR5 inhibitor with an IC₅₀ of 4.48 nM. HBI-2375 binds to the WINR5 and disrupts MLL1-WDR5 protein-protein interactions. HBI-2375 inhibits cancer cells proliferation and shows anti-tumor activity in AML mouse models, and increases tumor CD8 ⁺ cytotoxic T lymphocyte infiltration. HBI-2375 inhibits hERG with an IC₅₀ of 17 µM .

HY-P99650

Grisnilimab WT1	Transmembrane Glycoprotein	Cancer
Grisnilimab (WT1) is an IgG2a monoclonal antibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

HY-P1571

Nucleoprotein (396-404) NP 396	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

HY-113963

Ac-IETD-CHO	Apoptosis	Cancer
Ac- IETD- CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac- IETD- CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac- IETD- CHO also inhibits cytotoxic T lymphocytes induced cell death .

HY-P1569A

LCMV gp33-41 TFA 3 Publications Verification LCMV GP(33-41) M-peptide TFA; gp33 epitope TFA	Arenavirus	Inflammation/Immunology
LCMV gp33-41 (TFA), the carboxyl-extended 9-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .

HY-160768

OTUB2-IN-1	Deubiquitinase	Inflammation/Immunology Cancer
OTUB2-IN-1, a specific inhibitor of OTUB2 (K_D: ~12 μM), reduces PD-L1 protein expression in tumor cells and inhibits tumor growth by promoting robust intra-tumor infiltration of cytotoxic T lymphocytes (CTL) .

HY-W009245

Bz-RS-iSer(3-Ph)-OMe	HIV	Infection Cancer
Bz-RS-iSer(3-Ph)-OMe (compound 2), a Taxol derivative, inhibits HSV replication cycle at low cytotoxicity, blocks mitotic divisions of Vero cells, influences M-MSV induced tumor size and affects immune response by inhibiting PHA-induced T lymphocyte proliferation .

HY-156871

CAMK1D-IN-1	CaMK	Cancer
CAMK1D-IN-1 (compound I) is an inhibitor of CAMK1D, targeting cytotoxic T lymphocyte (CTL)-resistant tumor cells. CAMK1D impairs CTL-induced death receptor signaling and apoptosis by inhibiting caspases, making it a key and effective target for PD-L1-refractory tumors .

HY-P990303

Anti-Mouse 2C TCR Antibody (1B2)	Nuclear Factor of activated T Cells (NFAT)	Others
Anti-Mouse 2C TCR Antibody (1B2) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse 2C TCR. Anti-Mouse 2C TCR Antibody (1B2) recognizes determinants on the variable regions of both the α and β subunits of the TCR (T cell receptor) expressed by the mouse cytotoxic T lymphocyte clone 2C. Anti-Mouse 2C TCR Antibody (1B2) can be used for the detections of immunofluorescence and flow cytometry .

HY-P2495A

OVA (241-270) TFA	Biochemical Assay Reagents	Inflammation/Immunology
OVA (241-270) TFA, a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .

HY-P99760

Nurulimab BCD-145	CTLA-4	Cancer
Nurulimab (BCD-145) is an anti-cytotoxic *T lymphocyte* antigen-4 (anti-CTLA-4)** human monoclonal antibody. Nurulimab can be can be used in research of melanoma .

HY-P99027

Ieramilimab LAG525; IMP701; Hu5A8	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .

HY-P3742

Tyrosinase (192-200), human mouse	Tyrosinase MHC	Cancer
Tyrosinase (192-200), human mouse is a *HLA-B4403-restricted tyrosinase epitope with affinity for HLA-B4403 and HLA-B4402. Tyrosinase (192-200), human mouse binds to HLA-B4403* to form a complex, which is recognized by the autologous cytotoxic T lymphocyte clone 22/31 derived from melanoma. Tyrosinase (192-200), human mouse binds to HLA-B4402 to form a complex, which is recognized by the CTL clone 329B/5 derived from healthy HLA-B4402 donors. Tyrosinase (192-200), human mouse is applicable to melanoma-related research .

HY-106374

Elpamotide	VEGFR	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .

HY-P3333A

KSPWFTTL TFA	MHC	Inflammation/Immunology Cancer
KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-175604

SCL-1	PD-1/PD-L1	Cancer
SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor. SCL-1 can inhibit PD-1/PD-L1 binding. SCL-1 increases T cells, B cells and natural killer cells. SCL-1 exerts strong tumor growth inhibitory effects that were mediated by effector T-cell induction inside tumors and the up-regulated expression of long non-coding RNAs as neoantigens leading to cytotoxic T lymphocyte activation. SCL-1 can be used for the research of cancer, such as triple-negative breast cancer .

HY-P2495

OVA (241-270)	Biochemical Assay Reagents	Cancer
OVA (241-270), a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .

HY-P10593

Influenza A NP (383-391) (HLA-B27)	Transmembrane Glycoprotein Influenza Virus	Cancer
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .

HY-P990280

Anti-Mouse CD27 Antibody (RM27-3E5)	TNF Receptor Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-Mouse CD27 Antibody (RM27-3E5) is an agonistic rat-derived IgG2a κ type antibody, targeting to mouse CD27. Anti-Mouse CD27 Antibody (RM27-3E5) stimulates CD 27. Anti-Mouse CD27 Antibody (RM27-3E5) can be used for the researches of cancer and immunology, such as B16cOVA tumor .

HY-P990928

Mipletamig APVO-436	CD3 Interleukin Related	Inflammation/Immunology Cancer
Mipletamig (APVO-436) is a bispecific CD123 x CD3 monoclonal antibody. Mipletamig simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. Mipletamig can be used for the study of acute myeloid leukemia (AML) .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic* T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P5742

ELAAWCRWGFLLALLPPGIAG	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5742A

ELAAWCRWGFLLALLPPGIAG TFA	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Cancer
PL120131 is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors .

HY-142938

RORγt agonist 3	ROR	Inflammation/Immunology
RORγt agonist 3 is a potent agonist of RORγt. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 3 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136326A1, compound 23) .

HY-142937

RORγt agonist 2	ROR	Inflammation/Immunology
RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17) .

HY-P990041

Firastotug ADG-116	CTLA-4	Inflammation/Immunology Cancer
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .

HY-153209

Adjuvant-4	Biochemical Assay Reagents	Others
Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.

HY-P991139

Futermestotug	CTLA-4	Cancer
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .

HY-153209G

Adjuvant-4 (GMP)	Biochemical Assay Reagents	Others
Adjuvant-4 (GMP) is a GMP grade Adjuvant-4. Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.

Cat. No.	Product Name	Type

HY-153209G

Adjuvant-4 (GMP)	Fluorescent Dyes
Adjuvant-4 (GMP) is a GMP grade Adjuvant-4. Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.

HY-D3181

CyGbPF

Fluorescent Dyes

CyGbPF is a granzyme B-specific near-infrared fluorescent probe. CyGbPF can be cleaved by granzyme B to remove the peptide cage group, restoring near-infrared fluorescence. CyGbPF passively accumulates in mouse tumors, and its activated fluorescence correlates with granzyme B expression, CD8 ⁺cytotoxic T lymphocyte populations, and CD4 ⁺helper T lymphocyte populations in tumor tissues. CyGbPF is efficiently cleared by the kidneys, enabling the assessment of immune activation via optical urine analysis. CyGbPF allows real-time non-invasive evaluation of cancer immunotherapeutic efficacy in living animals. CyGbPF can be used in research on cancers such as breast cancer. Excitation wavelength/emission wavelength: approximately 658 nm/approximately 717 nm .

Cat. No.	Product Name	Target	Research Area

HY-P1569

LCMV gp33-41 3 Publications Verification LCMV GP(33-41) M-peptide; gp33 epitope	Arenavirus	Infection Inflammation/Immunology
LCMV gp33-41, the carboxyl-extended 9-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .

HY-P4193

AH1	MHC	Inflammation/Immunology Cancer
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8 ⁺ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I L ^d molecule. AH1 can be used for the research of colorectal carcinoma .

HY-P1907

Human Papillomavirus (HPV) E7 protein (49-57)	HPV	Cancer
Human Papillomavirus (HPV) E7 protein (49-57) is a cytotoxic T lymphocyte (CTL) epitope peptide derived from HPV16 E7 protein (sequence: RAHYNIVTF). Human Papillomavirus (HPV) E7 protein (49-57) induces E7_49-57-specific CTL responses. Human Papillomavirus (HPV) E7 protein (49-57) can be used for the research of cervical cancer .

HY-P3333

KSPWFTTL	MHC	Inflammation/Immunology Cancer
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

HY-P1571

Nucleoprotein (396-404) NP 396	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

HY-113963

Ac-IETD-CHO	Apoptosis	Cancer
Ac- IETD- CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac- IETD- CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac- IETD- CHO also inhibits cytotoxic T lymphocytes induced cell death .

HY-P1569A

LCMV gp33-41 TFA 3 Publications Verification LCMV GP(33-41) M-peptide TFA; gp33 epitope TFA	Arenavirus	Inflammation/Immunology
LCMV gp33-41 (TFA), the carboxyl-extended 9-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .

HY-P2495A

OVA (241-270) TFA	Biochemical Assay Reagents	Inflammation/Immunology
OVA (241-270) TFA, a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .

HY-P3742

Tyrosinase (192-200), human mouse	Tyrosinase MHC	Cancer
Tyrosinase (192-200), human mouse is a *HLA-B4403-restricted tyrosinase epitope with affinity for HLA-B4403 and HLA-B4402. Tyrosinase (192-200), human mouse binds to HLA-B4403* to form a complex, which is recognized by the autologous cytotoxic T lymphocyte clone 22/31 derived from melanoma. Tyrosinase (192-200), human mouse binds to HLA-B4402 to form a complex, which is recognized by the CTL clone 329B/5 derived from healthy HLA-B4402 donors. Tyrosinase (192-200), human mouse is applicable to melanoma-related research .

HY-106374

Elpamotide	VEGFR	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .

HY-P3333A

KSPWFTTL TFA	MHC	Inflammation/Immunology Cancer
KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P2495

OVA (241-270)	Biochemical Assay Reagents	Cancer
OVA (241-270), a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .

HY-P10593

Influenza A NP (383-391) (HLA-B27)	Transmembrane Glycoprotein Influenza Virus	Cancer
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic* T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P5742

ELAAWCRWGFLLALLPPGIAG	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5742A

ELAAWCRWGFLLALLPPGIAG TFA	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Cancer
PL120131 is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors .

HY-105039

Disomotide G209-2M; GP100:209-217(210M); MPS-22	Peptides	Cancer
Disomotide (G209-2M) is a melanoma antigen that enhances the generation of cytotoxic T lymphocytes (CTL) recognizing native G209 as well as melanoma .

HY-P2521

NS2 (114-121), Influenza	Influenza Virus	Infection Inflammation/Immunology
NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructural protein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 ⁺ cytotoxic T lymphocyte (CTL) in antiviral immune responses .

HY-P1835

CEF8, Influenza Virus NP (383-391)	Influenza Virus	Inflammation/Immunology
CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B ^2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic* T lymphocytes-mediated immunity .

HY-P10245

Fusion glycoprotein (92-106)	RSV	Inflammation/Immunology
Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratory syncytial virus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .

HY-P1862

HSV-gB2 (498-505)	HSV	Infection
HSV-gB2 (498-505) is an immunodominant epitope from herpes simplex virus (HSV) glycoprotein B residues 498-505, acts as H-2Kb-restricted and HSV-1/2-cross-reactive cytotoxic T-lymphocyte (CTL) recognition epitope .

HY-P10607

IALYLQQNW	EBV	Cancer
IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .

HY-P11145

Influenza HA (529-537)	Influenza Virus	Infection Inflammation/Immunology
Influenza HA (529-537) is the amino acid sequence (IYATVAGSL) at positions 529-537 of the hemagglutinin (HA) of the influenza A virus. Influenza HA (529-537) can be recognized by three different specificities (H1-specific, H2-specific, H1/H2 cross-reactive) of CD8 ⁺ cytotoxic T-lymphocyte (CTL) clones. Influenza HA (529-537) can be used to understand T-cell immune specificity and to design new vaccines .

HY-P1920

CEF19, Epstein-Barr Virus latent NA-3A (458-466)	EBV	Inflammation/Immunology
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .

HY-P3070

H2-D b restricted epitopes VSV Nucleoprotein (52-59)	MHC	Infection Others
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .

HY-P1571A

Nucleoprotein (396-404) TFA NP 396 TFA	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

HY-P10496A

MAGE-A1-derived peptide acetate	Peptides	Cancer
MAGE-A1-derived peptide acetate is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide acetate can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide acetate can be used in the study of tumor immunity .

HY-P10496

MAGE-A1-derived peptide	Peptides	Cancer
MAGE-A1-derived peptide is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide can be used in the study of tumor immunity .

HY-175057

Ac-IETD-CHO TFA	Apoptosis	Inflammation/Immunology Cancer
Ac-IETD-CHO TFA is a potent, reversible inhibitor of granzyme B and caspase-8. Ac-IETD-CHO TFA inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac-IETD-CHO TFA also inhibits cytotoxic T lymphocytes induced cell death .

HY-P10838A

PL120131 acetate	PD-1/PD-L1 Apoptosis	Cancer
PL120131 acetate is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors .

HY-P11397

VLPDVFIRCV	MHC	Cancer
VLPDVFIRCV, a melanoma antigen-derived peptide, is the intron sequence (nt 38-67) of the N-acetylglucosamine transferase V (GnT-V) gene. VLPDVFIRCV has a high affinity for MHC-I class molecules, but it cannot activate the immune response against natural tumor cells. The cytotoxic T lymphocytes (CTL) induced by VLPDVFIRCV can specifically lyse T2 cells loaded with this peptide in the chromium release experiment. VLPDVFIRCV can be used for vaccine design research .

HY-P11713

EBNA3B 399-408	EBV MHC	Infection Cancer
EBNA3B 399-408 is an immunodominant HLA-A11-restricted cytotoxic T-lymphocyte epitope in EBNA3B. EBNA3B 399-408 can be used in the research of EBV infection, empyema-associated lymphoma, and nasal natural killer cell lymphoma .

HY-P11390

BAGE (2-10)	MHC	Cancer
BAGE (2-10) is a *BAGE-encoded nonapeptide. BAGE (2-10) binds to the HLA-Cw1601** molecule to form an antigen recognized by autologous cytotoxic T lymphocytes. BAGE (2-10) can be used in melanoma research .

HY-106187B

MART-1 (27-35) (human) TFA		Cancer
MART-1 (27-35) (human) (TFA) is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) (TFA) can be used in studies related to melanoma .

HY-P11699

AAPDNRETF		Inflammation/Immunology
AAPDNRETF is a dominant minor histocompatibility antigen presented by H-2D ^b， which antigen is expressed in C57BL/6 mice and can be recognized by T cells from C3H.SW mice, thereby inducing a strong immune response. AAPDNRETF can induce graft-versus-host disease in irradiated C57BL/6 recipient mice via transfer of sensitized T lymphocytes. AAPDNRETF is applicable to the research of graft-versus-host disease .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9901

Ipilimumab 4 Publications Verification MDX-010; BMS-734016	CTLA-4	Cancer
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .

HY-P9948

Alemtuzumab Campath-IH	Apoptosis	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .

HY-P990116

Anti-Mouse osteopontin/SPP1 Antibody (103D6)	Osteopontin	Inflammation/Immunology
Anti-Mouse osteopontin/SPP1 Antibody (103D6) is a mouse-derived anti-mouse osteopontin/SPP1 IgG2c κ type antibody inhibitor. Anti-Mouse osteopontin/SPP1 Antibody (103D6) increases cytotoxic T lymphocyte lytic activity and suppresses colon tumor growth. Anti-Mouse osteopontin/SPP1 Antibody (103D6) ameliorates liver injury in common bile duct ligation (CBDL)-induced primary sclerosing cholangitis mice models .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

HY-P99762

Obrindatamab 1 Publications Verification MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P9918

Tremelimumab Ticilimumab; CP-675206	CTLA-4	Inflammation/Immunology Cancer
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .

HY-P99484

Botensilimab AGEN 1181	CTLA-4	Cancer
Botensilimab (AGEN 1181), a human anti-cytotoxic *T-lymphocyte* antigen 4 (CTLA-4)** monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .

HY-P990795

Anti-Mouse osteopontin/SPP1 Antibody (100D3)	Osteopontin	Inflammation/Immunology Cancer
Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonal antibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control (HY-P99981) .

HY-P99650

Grisnilimab WT1	Transmembrane Glycoprotein	Cancer
Grisnilimab (WT1) is an IgG2a monoclonal antibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .

HY-P990303

Anti-Mouse 2C TCR Antibody (1B2)	Nuclear Factor of activated T Cells (NFAT)	Others
Anti-Mouse 2C TCR Antibody (1B2) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse 2C TCR. Anti-Mouse 2C TCR Antibody (1B2) recognizes determinants on the variable regions of both the α and β subunits of the TCR (T cell receptor) expressed by the mouse cytotoxic T lymphocyte clone 2C. Anti-Mouse 2C TCR Antibody (1B2) can be used for the detections of immunofluorescence and flow cytometry .

HY-P99760

Nurulimab BCD-145	CTLA-4	Cancer
Nurulimab (BCD-145) is an anti-cytotoxic *T lymphocyte* antigen-4 (anti-CTLA-4)** human monoclonal antibody. Nurulimab can be can be used in research of melanoma .

HY-P99027

Ieramilimab LAG525; IMP701; Hu5A8	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .

HY-P990280

Anti-Mouse CD27 Antibody (RM27-3E5)	TNF Receptor Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-Mouse CD27 Antibody (RM27-3E5) is an agonistic rat-derived IgG2a κ type antibody, targeting to mouse CD27. Anti-Mouse CD27 Antibody (RM27-3E5) stimulates CD 27. Anti-Mouse CD27 Antibody (RM27-3E5) can be used for the researches of cancer and immunology, such as B16cOVA tumor .

HY-P990928

Mipletamig APVO-436	CD3 Interleukin Related	Inflammation/Immunology Cancer
Mipletamig (APVO-436) is a bispecific CD123 x CD3 monoclonal antibody. Mipletamig simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. Mipletamig can be used for the study of acute myeloid leukemia (AML) .

HY-P990041

Firastotug ADG-116	CTLA-4	Inflammation/Immunology Cancer
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .

HY-P991139

Futermestotug	CTLA-4	Cancer
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .

HY-P991354

GR-1405	PD-1/PD-L1	Cancer
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .

HY-P990848

Anti-CTLA-4/CD152 Antibody (BN13)	CTLA-4	Infection Inflammation/Immunology
Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human CTLA-4/CD152. Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. Anti-CTLA-4/CD152 Antibody (BN13) can be used for the researches of infection and immunology, such as human immunodeficiency virus (HIV) .

HY-P992361

HB0030	Transmembrane Glycoprotein	Cancer
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 ⁺ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .

HY-P991530

YH004	Biochemical Assay Reagents	Inflammation/Immunology Cancer
YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .

HY-P992177

AI-025	PD-1/PD-L1	Inflammation/Immunology Cancer
AI-025 is an anti-PD-1 antibody. AI-061, a combination formulation of AI-025 and ONC-392 (HY-P990042), inhibits the downregulation of cell activation and proliferation mediated by PD-1 and CTLA-4, thereby restoring immune function and activating cytotoxic T lymphocyte-mediated immune responses against tumor cells. AI-025 can be used in cancer research .

HY-P991827

Anti-Mouse CTLA-4 Antibody (UC10-4F10-11)	CTLA-4	Inflammation/Immunology
Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) reacts with mouse cytotoxic T lymphocyte antigen-4 (CTLA-4, CD152). Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) promotes T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .

HY-P991911

PLT012	Scavenger Receptor Class B type I (SR-BI）	Cancer
PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8 ⁺ tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8 ⁺ T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research .

HY-P992448

RC98	PD-1/PD-L1	Cancer
RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .

HY-P991918

KHK2840 IgG2-AAS	Transmembrane Glycoprotein Interleukin Related	Inflammation/Immunology Cancer
KHK2840 is a potent CD40 agonist with a K_d value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma .

Cat. No.	Product Name		Classification

HY-153209

Adjuvant-4		Adjuvant
Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.

HY-174713

Human FASLG mRNA		mRNA
Human FASLG mRNA encodes the human Fas ligand (FASLG) protein, a member of the tumor necrosis factor superfamily. The primary function of the FASLG is the induction of apoptosis triggered by binding to FAS. The FAS/FASLG signaling pathway is essential for immune system regulation, including activation-induced cell death (AICD) of T cells and cytotoxic T lymphocyte induced cell death. It has also been implicated in the progression of several cancers.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Cytotoxic T lymphocytes

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products